Oxurion Expands Services to Meet Growing Demand in GLP-1 Clinical Research

Oxurion NV, a biopharmaceutical company in Leuven, Belgium, has announced a new service offering through its subsidiary, Axiodis, focused on GLP-1 therapies and peptide therapeutics. This expansion responds to a growing global demand for biosimilars and next-generation peptide therapies, driven by expiring patents on key molecules like semaglutide.

The market for GLP-1 receptor agonists is projected to surpass $150 billion by 2029, positioning it as one of the fastest-growing sectors in global healthcare. Oxurion aims to capitalize on this by enhancing its clinical research capabilities through targeted acquisitions and organic development, intending to build a specialized European clinical research platform.

Oxurion's services, including biometrics, clinical data management, and biostatistics, support various peptide and metabolic disease programs. The company plans further expansion with potential strategic acquisitions in the CRO sector to bolster clinical operations and monitoring expertise.